Exdensur

Pharma

FDA rejection letters flag data concerns for AZ, GSK biologics

The FDA cited “critical data quality issues” in rejecting AZ's Saphnelo for SLE, and it ruled that GSK's Exdensur lacked “adequate evidence” in CRSwNP.

Angus Liu Mar 3, 2026 11:30am

As CEO, Luke Miels wants GSK to be more 'product-centric'

Feb 4, 2026 9:40am